The purpose of this webinar is to describe the process of coding for PrEP in WV and PA, discuss the implementation of billing for PrEP, and compare the different options for paying for PrEP.
This webinar will focus on the question of why there is a raging epidemic of addiction. The current opioid epidemic is a symptom of the fraying of the socio-economic fabric of rural United States. We will also look at the reasons why funding should be targeted to substance misuse, not to the drug of the moment.
At the end of the webinar, participants will be able to describe current guidelines and epidemiology for HIV testing among adolescents, identify key steps in educating health professionals on routine HIV testing for adolescents, and discuss lessons learned and how to implement these lessons learned across EHE regions.
This session will describe PrEP and the importance of adherence during the COVID-19 pandemic, barriers to PrEP that have been brought on by COVID-19, strategies to overcome barriers and promote adherence, and how telehealth can be used to promote PrEP.
This webinar will describe the process of vaccine development during COVID-19 and discuss the challenges and opportunities associated with vaccine development.
Abstract: Acute lung injury (ALI) is a form of acute respiratory failure, having an estimated annual incidence of 200,000 with a 40% mortality rate in the United States alone. Patients suffering from hemolytic diseases such as sepsis, malaria, and sickle cell disease are placed at a greater risk of developing ALI because of the excess amount of heme release that occurs during the pathogenesis of these diseases. Free heme is known to be a danger associated molecular pattern (DAMP) molecule and previous reports from our lab have identified particularly toxic effects apply to the lung endothelial barrier, ultimately contributing to ALI. However, the cellular mechanism of how heme is able to cause endothelial damage remains largely unknown. Recent studies have revealed that heme is able to induce the activation of nod-like receptor 3 (NLRP3) inflammasome in monocytes, which is followed by the maturation and release of inflammatory molecules Interleukin-1 (IL-1) and Interleukin-18 (IL-18). Therefore, in this study we hypothesized that heme induces NLRP3 in pulmonary microvascular endothelial cells, resulting in destructive inflammatory activity that leads to the development of ALI. To test this hypothesis, we challenged human primary microvascular endothelial cells (HMVEC-Ls) with heme and assessed cell death, barrier integrity, cytokine release, and corresponding inflammasome activation. Heme challenge of HMVEC-Ls produced a 75% decrease in barrier resistance as compared to vehicle, measured via electrical cell-substrate impedance sensing (ECIS). This barrier instability was concomitant with a significant 3-fold increase in IL-18 (p=0.046) release and an increase in NLRP3 protein, measured through extracellular supernatant and western blot respectively. Importantly, inhibition of NLRP3 resulted in a 35% increase in barrier integrity, which corresponded to a 20% decrease in lung wet-to-dry weight ratio in mice that were injected with heme. These results demonstrate that heme mediated endothelial damage involves an inflammatory response associated with NLRP3 inflammasome activation, which is a potential target for therapeutic intervention. Future studies are warranted to confirm heme-mediated inflammasome formation and activation. Identifying specific molecular and cellular mechanisms by which heme damages the vascular endothelium in the pathogenesis of ALI is important for decreasing morbidity among patients and improving the overall health of the public.
Advisor: Dr. Robbie Mailliard
Last Updated On Tuesday, April 17, 2018 by Abby Kincaid
Created On Tuesday, April 17, 2018
Click to enter calendar events or share news and announcements.